Olanzapine in Schizophrenia and Affective Disorders
KeywordsSchizophrenia Bipolar Disorder Haloperidol Olanzapine Drug Exposure
Supported in part by a Josep Font Research Grant from the Hospital Clínic of Barcelona (to Juan Undurraga); the Instituto de Salud Carlos III through the Centro para la Investigación Biomédica en Red de Salud Mental (CIBERSAM) [to Juan Undurraga, Eduard Vieta and Francesc Colom]; a Miguel Servet postdoctoral contract (CP08/00140) and an FIS (PS09/01044) [Francesc Colom]; and the Generalitat de Catalunya to Bipolar Disorders Group (2009 SGR 1022) [Juan Undurraga, Eduard Vieta and Francesc Colom].
Professor Vieta is a consultant or grant recipient with Almirall, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest Research Institute, Gedeon Richter, GlaxoSmithKline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Sanofi, Servier, Schering-Plough, Shire, Takeda and United Biosource Corporations. Dr Francesc Colom has served as advisory or speaker for the following companies: Adamed, AstraZeneca, Bristol-Myers, Eli-Lilly, GlaxoSmithKline, Lundbeck, MSD-Merck, Otsuka, Pfizer Inc., Sanofi-Aventis, Shire and Tecnifar. He has received copyright fees from Cambridge University Press, Solal Ed., Ars Médica, Giovani Fioriti Ed., Medipage, La Esfera de Los Libros, Morales i Torres Ed, Panamericana, Mayo Ed. and Columna. Dr Mauricio Tohen was an Eli Lilly employee and has received honoraria from or been a consultant for AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, Johnson & Johnson, Sepracor, Otsuka, Merck, Sunovion, Forest, Lundbeck and Wyeth. His spouse is a current employee and minor stockholder of Eli Lilly. Dr Juan Undurraga declares no conflicts of interest.